From Yahoo Finance: 2025-04-09 11:11:00

Pharmaceutical stocks are facing a rough week as President Trump prepares to unveil new tariffs on pharmaceutical imports, causing investor nervousness. Shares of Roche Holding, Eli Lilly, and AstraZeneca are all down, with AstraZeneca taking the biggest hit.

The recent bad tariff news has already led to significant stock declines for Roche, Lilly, and AstraZeneca. The president’s upcoming announcement is expected to target pharmaceutical imports into the U.S. and potentially incentivize drug companies to move their operations stateside.

Trump’s previous tariffs spared pharmaceutical imports, but with the U.S. importing a significant amount of finished medicines, mainly from China, the new tariffs could impact the industry. AstraZeneca, with a large portion of assets abroad, may be at higher risk, while Roche and Lilly have more U.S.-based operations.

AstraZeneca, Roche, and Lilly all have varying levels of assets and revenue in the U.S., with AstraZeneca potentially being the most vulnerable to new tariffs. Despite the raw numbers, the impact of tariffs may vary based on the companies’ ability to shift production domestically.

While the tariff risk presents uncertainty for pharmaceutical stocks, the long-term impact may not be as severe as feared. Investors should consider the potential effects on AstraZeneca and other pharmaceutical companies before making investment decisions.

Read more: Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today